Cancer Therapy

Investigational new drug applications filed for M-Vax, O-Vax

Published in Vaccine Weekly, November 6th, 2002

Avax Technologies, Inc., (AVXT) announced the submission of investigational new drug applications (IND) for M-Vax and O-Vax, its AC Vaccine technology product candidates for the treatment of melanoma and ovarian cancers, with the U.S. Food and Drug Administration (FDA).

If, after a 30-day review period FDA has no questions, the company will be able to commence its clinical trials.

David L. Tousley, president and chief operating officer of Avax stated, "This is an important milestone in the continuing development of the frozen AC Vaccine technology. Our team has done a great job in completing the necessary product development activities, assay...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-11-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry